Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
0.12% chlorhexidine mouthrinse · 1 trial · 1 indication
Plaque scores were assessed using Turesky Modification of the Quigley Hein Index and categorized as 0: No plaque; 1: Slight flecks of plaque at the cervical margin of the tooth;2: A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth;3: A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth;4: Plaque covering at least 1/3 but less than 2/3 of the crown of the tooth;5: Plaque covering 2/3 or more of the crown of the tooth. The interproximal plaque index was calculated by taking the average of plaque scores over the mesiofacial, distofacial, mesiolingual and distolingual surfaces in the upper and lower jaws for a participant.
| Arm | Type | Description |
|---|---|---|
| 0.12% Chlorhexidine Mouthrinse | ACTIVE_COMPARATOR | Commercially available 0.12% Chlorhexidine mouthrinse |
| Cosmetic mouthrinse | ACTIVE_COMPARATOR | Commercially available cosmetic mouthrinse |
| Sterile Water | PLACEBO_COMPARATOR | Sterile Water |
| Name | Type | Description |
|---|---|---|
| 0.12% chlorhexidine mouthrinse | DRUG | commercially available 0.12% chlorhexidine mouthrinse |
| Cosmetic mouthrinse | OTHER | Commerically available cosmetic mouthrinse |
| Sterile water | OTHER | Sterile water |
Inclusion Criteria: * Good general and oral health * At least 20 natural gradable teeth * Mean plaque score (Turesky Modification of the Quigley Hein Index) of greater than or equal to 2.00 at the first baseline visit
0.12% chlorhexidine mouthrinse is used for plaque control in healthy subjects. It is being studied in a clinical trial to evaluate its effect on plaque re-growth. The drug is a small molecule and is currently in Phase 2 clinical development.
0.12% chlorhexidine mouthrinse is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to assess the mouthrinse's efficacy in healthy subjects.
0.12% chlorhexidine mouthrinse is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its effect on plaque re-growth in healthy subjects.
0.12% chlorhexidine mouthrinse is being studied in one clinical trial, identified as NCT01122862. This Phase 2 trial, titled 'Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth,' has been completed. The trial enrolled 23 healthy subjects in the United States.
0.12% chlorhexidine mouthrinse is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The drug is being studied for its effect on plaque re-growth in healthy subjects, but it has not yet received regulatory approval.